Mosunetuzumab

Cytokine Release Syndrome

Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving LUNSUMIO. Initiate treatment with the LUNSUMIO step-up dosing schedule to reduce the risk of CRS. Withhold LUNSUMIO until CRS resolves or permanently discontinue based on severity. 

Package inserts

Keywords: Lunsumio
Updated: December 2022